Small Molecules

02 Aug 2018 Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension
31 Jul 2018 Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
31 Jul 2018 Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1 Study of Guadecitabine (SGI-110) in Treatment-Naïve AML Patients Ineligible to Receive Intense Induction Chemotherapy
31 Jul 2018 Active Biotech provides update on laquinimod in Huntington's disease
31 Jul 2018 Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA® in Combination with KEYTRUDA®as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial
31 Jul 2018 Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma
30 Jul 2018 RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
30 Jul 2018 Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints
30 Jul 2018 FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis
30 Jul 2018 CStone's MEK Inhibitor CS3006 Receives IND Approval in China
28 Jul 2018 FDA Approves PERSERIS™ (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
27 Jul 2018 eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
27 Jul 2018 European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following Appeal
27 Jul 2018 Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)
27 Jul 2018 Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava™ (eravacycline) as a Treatment for Complicated Intra-Abdominal Infections
27 Jul 2018 Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD
27 Jul 2018 Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease
27 Jul 2018 Principia Confirms Human CNS Exposure and Good Tolerability of Oral BTK Inhibitor PRN2246
27 Jul 2018 Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene
27 Jul 2018 BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
26 Jul 2018 Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator
26 Jul 2018 Proclara Biosciences Announces Initiation of NPT189 Clinical Development for Systemic Amyloidoses and Provides Pipeline Update
26 Jul 2018 Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
26 Jul 2018 Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
26 Jul 2018 Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up